Drugs / GB222
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04178057 | Oct 2018 → Dec 2020 | brain neoplasm | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04175158 | Apr 2017 → Aug 2020 | non-small cell lung carcinoma | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB222 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04175158 ↗ |
| Action | Inhibit | “antivascular endothelial growth factor” NCT04178057 ↗ |
| Modality | Monoclonal antibody | “Recombinant humanized antivascular endothelial growth factor monoclonal antibody injection” NCT04178057 ↗ |
| Route | Intravenous | “intravenous infusion” NCT04178057 ↗ |